MedTrace Logo

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of the rotigotine transdermal patch in reducing anxiety in people with Parkinson's disease.

Conditions

  • Anxiety Disorders
  • Parkinson Disease

Interventions

DRUG

rotigotine transdermal patch

Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily

DRUG

placebo

Participants will receive a placebo transdermal patch to be worn daily

Sponsors & Collaborators

Principal Investigators

  • Gregory Pontone, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02365870 on ClinicalTrials.gov